Drug Trial Radar · NCT07340697
Evaluate RLS-1496 Topical Cream for Actinic Keratosis
Last checked: Nov 20, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Feb 3, 2026
Primary completion
May 27, 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- Rubedo Life Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial will assess the safety and tolerability of topical application of RLS-1496 cream to lesions and adjacent skin on the left forearm of adults with actinic keratoses (AK) on the arms. The right forearm will remain untreated as a control. The therapeutic objective of topical treatment with RLS-1496 cream is to clear or decrease the number of AK in the treated area, per lesion counts performed by the Investigator. The main questions it aims to answer are: * Is it safe to apply topical RLS-1496 cream to treat AK once daily for 28 days? * Does topical RLS-1496 lower the number of AKs or eliminate AKs in a treated area when applied once daily for 28 days? Researchers will compare results on the left (treated with RLS-1496) and right (no treatment) forearm. Participants will apply RLS-1496 to an identified area on the left forearm once each day for 28 days and have intermittent clinic visits to examine the arms and have the AK lesions counted until 28 days after the last application of RLS-1496. Participants will also have small skin biopsies on the arms.
Conditions
- Actinic Keratosis (AK)
Interventions
RLS-1496 1.0% creamDrug
Topical cream to be applied to lesions and peri-lesional skin.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of multiple doses of topical RLS-1496 creamTime frame: 57 days
- Proportion of individual AK lesions with complete (100%) clearanceTime frame: 29 days
- Complete (100%) clearance of AK lesionsTime frame: 29 days
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Burke Pharmaceutical Research
Hot Springs, Arkansas
Minnesota Clinical Study Center
New Brighton, Minnesota
Schlessinger MD Skin Research Center
Omaha, Nebraska
Austin Institute for Clinical Research
Pflugerville, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.